What Are the Classifications of Myelodysplastic Syndromes?

This content has been reviewed and approved by

Hagop M. Kantarjian, MD
Chairman & Professor, Leukemia Department
MD Anderson Cancer Center
University of Texas
 

Myelodysplastic syndromes are generally classified into “lower risk MDS” and “higher risk MDS.” Your physician can tell you which classification you fall under based on the characteristics of your disease. The three primary characteristics are percent of marrow blasts (immature cells), chromosome abnormalities, and blood counts (platelets, red cells, and white cells). 

In general, if you have blasts that are less than 10 percent of total blood cells, you fall in the lower risk category. Blasts equal to or above 10 percent, many abnormal chromosomes, and low platelet and red and white blood cell counts put you in the higher risk category. 

The most commonly used classification system is called the International Prognostic Scoring System (IPSS). The table below shows how your risk category correlates to the IPSS score. A score of 0 to 1 is in the lower risk category, whereas a score above 1 places you in the higher risk category. 

 

IPSS Risk 

Score 

Average Survival 

Low 

0 

5-6 years 

Intermediate 1 

0.5-1 

3-4 years 

Intermediate 2 

1.5-2 

1-1.5 years 

High 

= 2.5 

4-6 months 

 

These categories help determine the type of treatment you will receive. 

 

This content was last modified on August 11, 2007 .
Latest Cancer News
ACOG Updates Cervical Cancer Screening Guidelines

November 20, 2009 — The American College of Obstetricians and Gynecologists (ACOG) has revised its cervical cancer screening recommendations: the organization now recommends that women begin screening at the age of 21 and receive screening at less frequent intervals. These recommendations will be published in the December 2009 issue of Obstetrics and Gynecology.

New Velcade®-melphalan Transplant Regimen for Multiple Myeloma

November 20, 2009 — Researchers from France have reported encouraging results with adding Velcade® (bortezomib) to high-dose melphalan followed by autologus stem cell infusion for initial treatment of patients with newly diagnosed multiple myeloma. The details of this Phase II study appeared in an early online publication in Blood on November 2, 2009.

Folic Acid May Be Beneficial in Patients with Recurrent Colorectal Adenoma Who Are Folate Deficient

November 20, 2009 — Researchers affiliated with the Health Professional Follow-Up Study and the Nurses’ Health Study have reported that folic acid supplementation in patients with recurrent colorectal adenoma was not protective or harmful in most patients. However, patients who were folate deficient had a significant 39% decrease in adenoma recurrence. The details of this study appeared in an early online publication on October 28, 2009 in the American Journal of Clinical Nutrition.

Select news items provided by Reuters Health